Schering-Plough has awarded ten $5,000 scholarships to high school seniors with asthma who are pursuing higher education. The recipients demonstrated outstanding performance and a track record of achievement in their entry category.
Tibotec presents data from the OPERA-1 Phase IIa trial showing dose-dependent antiviral activity of TMC435, with mean reductions in HCV RNA of 2.63 and 3.47 log10 IU/mL. Nearly 90% of patients achieved undetectable viral load within 28 days of combined treatment with standard care.
New report finds lung cancer media coverage is on the rise, but with a significant decrease in positive coverage and an overemphasis on smoking as a risk factor. Despite this, breast cancer coverage remains more favorable, often featuring personal stories of survivors.
Phase III trials demonstrate iclaprim's effectiveness in treating complicated skin and skin structure infections caused by Gram-positive bacteria, including MRSA. The antibiotic showed a high clinical cure rate similar to linezolid and was well-tolerated with a favorable safety profile.